WASHINGTON DC. WA, September 24, 2026 — Alzheimer’s care in the U.S. is becoming more expensive, and it’s changing how money moves around healthcare. The costs for health and long-term care associated with dementia due to Alzheimer’s and other dementias are projected to reach $409 billion by 2026. That figure doesn’t even include the value of unpaid family caregivers.
The Magnitude of the Financial Burden
Last year, nearly 13 million Americans committed over 19 billion hours of unpaid care to those with dementia. Public health data published by the Centers for Disease Control and Prevention values that labor at more than $446 billion a year—a total cost that never makes it onto a hospital bill. The burden is not borne entirely by Medicare, Medicaid, families, and their employers; rather, each bears a portion of an ever-expanding burden as the population ages.
The future looks even bleaker for federal health programs over the longer term. Unless breakthroughs for new treatments emerge, the cost to Medicare of caring for the disease will continue climbing rapidly over the next few decades. This course has propelled both government bodies and private businesses to root around more for mitigation and convenience.
Where New Money Is Going
Biogen and Eisai spent billions researching disease-modifying therapies that reduce amyloid in the brain. Lecanemab and donanemab are two treatments which slow cognitive deterioration in patients diagnosed at a fairly early stage. Health econ research shows that the price for a treatment course can be comparable to the cost of a new car.
The other major investment target this year has become diagnostic technology. A blood test intended to assist in the diagnosis of Alzheimer’s disease in patients displaying signs of dementia has been cleared by the U.S. Food and Drug Administration. Now, that green light allows much cheaper and less invasive screening to be done on far more patients compared to brain scans today.
Why Early Detection Matters Financially
It makes a huge difference for patients and payers when you catch Alzheimer’s earlier. Individuals that initiate treatment for the disease early on while still in mild cognitive impairment have been reported with slower disease progression than those diagnosed at later stages. The hold-up can be the difference of months, even years, in nursing homes and constant treatment avoidance expenses.
As private investment has increased, so too has federal research funding in recent years, as advocates argue it still lags behind the problem scale. For example, the National Institutes of Health sought approximately $4 billion for Alzheimer’s and related dementia research in fiscal year 2023. Advocates say that despite the rising toll of dementia, funding is still relatively small compared to cancer research.
The Investor & Patient Road Ahead
Health systems are now considering whether broader blood-test screening could help to offset expensive new drug therapies across time. Insurers have been somewhat reluctant to cover the latest treatments broadly, with restrictions based on cost and modest average benefit per patient as provided in peer-reviewed medical literature. That tension between the promise of science and financial realities is likely to dominate investing for many years to come.
Continuing with our sector, advocacy groups are urging Congress to provide broader funding for research and caregiver support programs. They argue that the costs of missing a diagnosis at an earlier stage mean even one dollar spent could be far smaller than the return. And with millions more Americans likely to get Alzheimer’s by the mid-21st century, the financial incentive for getting this right continues to rise.
Driven by both scientific advances and the sheer size of the potential market, pharmaceutical companies have greatly expanded their pipelines. A number of other potential treatments are in later-stage clinical trials and are based on biological mechanisms that differ from the approved drugs. The renewed investor interest, particularly in many dementia-focused biotechnology companies, follows a series of high-profile failures for drugs treating the disease.
As more workers struggle to balance jobs and caring for aging parents, employers also are starting to incorporate caregiving costs into their own planning. Some businesses provide additional benefits relating to dementia, such as caregiver leave or other services like specialty care management. That change recognizes the reality that Alzheimer’s expenses reach far beyond a hospital and into the daily workplace. State health departments and economic research bodies, including resources supported by the U.S. Department of Health and Human Services, continue to evaluate long-term care financing.
Additionally, disability coverage frameworks monitored by the Social Security Administration remain a key factor for families managing early-onset cases. As the cost of the disease continues to grow across the country, it remains an open question whether that patchwork approach can close the funding gap in a way that matters.
